Geneva, Switzerland — May 13, 2025
TBS® (Trabecular Bone Score®) has recently been included in the national guideline for the diagnosis and treatment of osteoporosis in Slovakia.
This marks another milestone in the global adoption of TBS®, now recognized in more than 30 national and international clinical guidelines. It’s inspiring to see more countries embracing tools that enable early diagnosis, personalized care, and long-term fracture prevention.
These guidelines are aligned with European and global best practices and support clinical decision-making across specialties.
About Medimaps
Medimaps (Medimaps Group SA) is a medtech AI company on a mission to help clinicians catch what routine imaging misses — every scan, every patient — for better care, building toward an era where healthy bones are the norm.
The creators of Trabecular Bone Score® (TBS®) — the global standard in bone microarchitecture assessment, cited in more than 35 international clinical guidelines and supported by 1,600+ peer-reviewed publications — Medimaps develops imaging software that helps clinicians see bone quality, not just bone density, and predict fracture risk from the imaging they already perform.
Following its merger with Radiobotics, an award-winning Danish MedTech company, Medimaps is building a clinical portfolio spanning the MSK care continuum — from TBS Reveal™, opportunistic bone fragility assessment from routine X-rays, to TBS Osteo™, for osteoporosis fracture risk assessment on DXA, to RBfracture™, designed to support emergency and radiology teams with detection of trauma-related findings on X-ray.
Medimaps is headquartered in Geneva, Switzerland, with offices in Denmark, France, and the US, with technology deployed in more than 90 countries. Medimaps is certified to ISO 13485:2016 and MDSAP. Learn more at medimaps.ai.
